Propanc Biopharma, Inc. (PPCB) intrinsic value & 10-year financials
Propanc Biopharma, Inc. (PPCB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.34
- Market cap
- $1.4M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 42.7%
- Free cash flow (FY2025)
- —
PPCB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$58.9M | -$14.85 | — | — | -1068.3% |
| FY2024 | — | -$1.8M | -$0.02 | — | — | 46.7% |
| FY2023 | — | -$2.7M | -$0.04 | — | — | 71.5% |
| FY2022 | — | -$2.7M | -$0.04 | — | — | 87.7% |
| FY2021 | — | -$2.4M | — | — | — | 75.3% |
| FY2020 | — | -$4.7M | — | — | — | 141.7% |
| FY2019 | — | -$5.8M | — | -$2.1M | — | 108.6% |
| FY2018 | — | -$7.0M | — | — | — | 188.2% |
| FY2017 | — | -$7.9M | — | — | — | 314.4% |
| FY2016 | $0 | -$9.4M | — | -$4.5M | — | 461.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Propanc Biopharma, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Propanc Biopharma, Inc. has earned high returns on invested capital, averaging 53.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Propanc Biopharma, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Propanc Biopharma, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.